Investigational Drug Information for Hetrombopag
✉ Email this page to a colleague
What is the drug development status for Hetrombopag?
Hetrombopag is an investigational drug.
There have been 31 clinical trials for Hetrombopag.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2023.
The most common disease conditions in clinical trials are Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, and Anemia, Aplastic. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Peking Union Medical College Hospital, and Institute of Hematology & Blood Diseases Hospital.
There are three US patents protecting this investigational drug and forty international patents.
Summary for Hetrombopag
| US Patents | 3 |
| International Patents | 40 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2023-04-01) |
| Vendors | 15 |
Recent Clinical Trials for Hetrombopag
| Title | Sponsor | Phase |
|---|---|---|
| The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial | Shandong University | Phase 2 |
| Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
Clinical Trial Summary for Hetrombopag
Top disease conditions for Hetrombopag
Top clinical trial sponsors for Hetrombopag
US Patents for Hetrombopag
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Hetrombopag | ⤷ Sign Up | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | Jiangsu Hengrui Medicine Co. Ltd. (Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co. Ltd. (Shanghai, CN) | ⤷ Sign Up |
| Hetrombopag | ⤷ Sign Up | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | Jiangsu Hengrui Medicine Co., Ltd. (CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (CN) | ⤷ Sign Up |
| Hetrombopag | ⤷ Sign Up | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | Jiangsu Hengrui Medicine Co., Ltd. (CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Hetrombopag
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Hetrombopag | Australia | AU2009207966 | 2028-01-10 | ⤷ Sign Up |
| Hetrombopag | Brazil | BRPI0907234 | 2028-01-10 | ⤷ Sign Up |
| Hetrombopag | Canada | CA2711535 | 2028-01-10 | ⤷ Sign Up |
| Hetrombopag | China | CN101481352 | 2028-01-10 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
